Cardiology
GLP-1 receptor agonists in cardiometabolic and obesity research, including cardiovascular outcome trials and mechanistic studies.
Synthesized from 12 evidence-backed clinical questions linked to this topic — 4 supporting the intervention, 2 against the intervention.
The placed evidence leans toward benefit
4
Favor benefit
33% of all
2
Favor harm
17% of all
6 more (50%) still untested — not placed on the axis.
Low certainty on 50% of questions
Does glp-1 receptor agonist vs placebo improve outcomes in orthopaedic surgery?
Low Certainty− Favors harmglp-1 receptor agonist vs placebo
2 studies (392,065 patients) provide low-certainty evidence against benefit of glp-1 receptor agonist for the outcome in orthopaedic surgery.
Does glp-1 receptor agonists vs dpp-4 inhibitors improve outcomes in Diabetes Mellitus, Type 2?
Low Certainty+ Favors benefitglp-1 receptor agonists vs dpp-4 inhibitors
4 studies (276,715 patients) provide low-certainty evidence for benefit of glp-1 receptor agonists for the outcome in Diabetes Mellitus, Type 2.
No claims extracted for this topic
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Utilization of glucagon‐like peptide‐1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database
Diabetes Obesity and Metabolism — Hirose N — Nov 2021
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease
Journal of Hypertension — Kumarathurai P — Feb 2017
Comparative effectiveness of cardiovascular, renal and safety outcomes of second‐line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta‐analysis of randomised controlled trials
Diabetic Medicine — Sim R — Dec 2021
Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings
Journal of Orthopaedic Surgery and Research — Uğur F — Oct 2025
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
GLP-1 receptor agonists (also known as GLP-1, GLP-1 RA, incretin). GLP-1 receptor agonists in cardiometabolic and obesity research, including cardiovascular outcome trials and mechanistic studies.
Synapse tracks 1 specific clinical question in GLP-1 receptor agonists, synthesizing the evidence for it independently: "Does glp-1 ra vs placebo improve All-Cause Mortality in lumbar fusion?".
As of 2026-09-09, the scientific consensus on GLP-1 receptor agonists is unknown. No claims extracted for this topic
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/peptide-glp-1.
Deterministic synthesis from Synapse's enriched corpus — 81 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every GLP-1 receptor agonists paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search GLP-1 receptor agonists papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis
Frontiers in Endocrinology — Wang Y — Mar 2022
Across this topic’s most recent indexed papers.
